Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Vonage Communications APIs allow developers to easily enhance and build intelligent, intuitive customer experiences directly into their existing applications and devices
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Ram’s appointment follows the launch of the CDI India division in October 2021.
The division is expected to grow to over a 100-member strong team by 2022
It has planned an investment of over Rs 80 crore in the next five years
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
Subscribe To Our Newsletter & Stay Updated
